Racura Oncology: Inside the $3.22M raise powering a lung cancer trial

25 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Stockhead’s Tylah Tully speaks with Racura Oncology (ASX:RAC) executive chair Dr Pete Smith about the company’s freshly secured $3.22 million in additional funding to accelerate its upcoming HARNESS-1 Phase 1a/b lung cancer trial.

Dr Smith explains how unexpected investor interest fast-tracked the capital raise, ensuring the company can begin patient recruitment with full financial certainty.

With the first patients expected to enrol in Q1 next year, he outlines a busy six months ahead, including real-time updates from the company’s open-label studies and new preclinical data exploring RC220’s potential across additional targeted therapy classes.
_____
For more free daily ASX news, visit:
???? https://stockhead.com.au

Subscribe to the free newsletter:
???? https://stockhead.com.au/subscribe

Follow:
https://linkedin.com/company/stockhead
https://facebook.com/StockheadAU
https://twitter.com/StockheadAU
Apple News: ???? https://apple.news/T1RAxifC9TtOJHZYNLJBAbA
Threads: ???? https://threads.net/@stockheadau
______

#asx #stockhead #investing #stockmarket #news #markettrends #asxnews #cancer #biotech #drugdevelopment
Categoria
Oncology
Commenta per primo questo video.

Prossimo